Related Experiment Video
Updated: May 1, 2026
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
Published on: August 1, 2018
Immunohistochemical analysis of PDK1 expression in breast cancer
1Institute of Pathology Charité, University Hospital Berlin, 10117 Berlin, Germany. ruza.arsenic@charite.de.
Background:
3-phosphoinositide-dependent protein kinase-1 (PDK1) functions downstream of phosphoinositide 3-kinase (PIK3) and activates members of the AGC family of protein kinases that are known to play crucial roles in physiological processes associated with cell metabolism, growth, proliferation and survival. Changes in the expression and activity of PDK1 and several AGC kinases have been linked to human disease, including cancer.
Methods:
We used immunohistochemical analysis to determine PDK1 expression in 241 tumors from patients with breast cancer in which we had previously analyzed PIK3CA mutation status.
Results:
Moderate or high expression of PDK1 was observed in 213 of the 241 cases (88%). There was no correlation between PIK3CA mutation status and PDK1 overexpression.
Conclusion:
Our findings indicate that PDK1 is independently activated in breast cancer and not only as part of the PIK3CA pathway, suggesting that PDK1 plays a specific and distinct role from the canonical PIK3/Akt pathway and promotes oncogenesis independently of AKT. Our data implicate PDK-1 and downstream components of the PDK-1 signaling pathway as promising therapeutic targets for the treatment of breast cancer.
Insights
3-phosphoinositide-dependent protein kinase-1 (PDK1) is frequently overexpressed in breast cancer, independent of PIK3CA mutations. This suggests PDK1 is a promising therapeutic target for breast cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- 3-phosphoinositide-dependent protein kinase-1 (PDK1) is crucial for cell metabolism, growth, proliferation, and survival.
- Altered PDK1 and AGC kinase activity are linked to human diseases, including cancer.
Purpose of the Study:
- To investigate PDK1 expression in breast cancer tumors.
- To determine the relationship between PDK1 expression and PIK3CA mutation status.
Main Methods:
- Immunohistochemical analysis of PDK1 expression.
- Analysis of 241 breast cancer tumors with known PIK3CA mutation status.
Main Results:
- Moderate or high PDK1 expression was found in 88% of breast cancer cases.
- No correlation was observed between PIK3CA mutation status and PDK1 overexpression.
Conclusions:
- PDK1 is independently activated in breast cancer, suggesting a role distinct from the canonical PIK3/Akt pathway.
- PDK1 promotes oncogenesis independently of AKT.
- PDK1 and its downstream signaling pathway components are potential therapeutic targets for breast cancer.
